| Literature DB >> 26346690 |
Anna Papadopoulou1, Panayiotis Kouis2, Nikos Middleton3, Ourania Kolokotroni4, Themistokles Karpathios5, Polyxeni Nicolaidou5, Panayiotis K Yiallouros6.
Abstract
BACKGROUND: Polymorphisms in the vitamin D receptor (VDR) gene have been studied in immune-related disorders either as independent contributors or in combination with vitamin D concentration. Vitamin D and VDR have been independently linked to asthma susceptibility. We investigated whether VDR variants were associated independently or in relation to vitamin D levels with asthma in Cypriot adolescents.Entities:
Keywords: Adolescents; Asthma; Polymorphisms; VDR; Vitamin D
Year: 2015 PMID: 26346690 PMCID: PMC4559891 DOI: 10.1186/s40248-015-0025-0
Source DB: PubMed Journal: Multidiscip Respir Med ISSN: 1828-695X
Fig. 1Course of the study: from the 19,849 participants (11–12 years) in Survey 1, a random sample of 3982 adolescents (15–17 years) participated in Survey 2. All (n = 297) subjects from the 3982 sample, who reported wheezing in the last 12 months were invited to participate as cases. A sample of 932 children with no diagnosis of asthma and no wheezing in the past 12 months were invited to participate as controls
Descriptive statistics for the study population
| NWNA (Controls) ( | CUW (Wheezers) ( |
| CUWA (Active Asthmatics) ( |
| |
|---|---|---|---|---|---|
| Age (yrs)a | 17.0 (15.9–18.0) | 17.0 (16.0–18.1) | 0.360 | 16.9 (15.9–18.1) | 0.549 |
| Sex (% male)b | 40.5 % | 43.1 % | 0.517 | 43.5 % | 0.626 |
| Vitamin D levels (ng/ml)a | 22.9 (10.9–35.9) | 22.9 (10.5–23.8) | 0.946 | 21.1 (8.8–30.81) | 0.017 |
| Sensitization (% positive)b | 25.7 % | 41.4 % | <0.001 | 52.0 % | <0.001 |
| Rhinitis (% positive)b | 18.4 % | 41.5 | <0.001 | 57.4 % | <0.001 |
| FVC (% predicted)a | 103.8 (72.7–135.9) | 104.9 (77.1–148.3) | 0.531 | 105.6 (78.0–153.6) | 0.484 |
| FEV1 (% predicted)a | 99.3 (69.6–125.3) | 99.1 (72.9–130.5) | 0.860 | 97.6 (62.0–125.6) | 0.398 |
NWNA Never Wheezing Never Asthma, CUW Current Wheezing, CUWA Current Wheezing and Asthma
aMean and 95 % CI, Independent sample t test for equality of means (2-sited significance)
bPercentage, χ 2 test (asymptomatic 2-sited significance)
Genotypic and allelic association analysis of VDR single-nucleotide polymorphisms between NWNA and CUW
| SNP | Genotypic association | Allelic association | |||||||
|---|---|---|---|---|---|---|---|---|---|
| NWNA ( | CUW ( |
|
| NWNA ( | CUW ( | OR (95 % CI) |
| ||
| BsmI | |||||||||
| BB | 127 (20.1 %) | 38 (21.2 %) | |||||||
| Bb | 327 (51.8 %) | 103 (57.5 %) | B | 581 (46 %) | 179 (50 %) | ||||
| bb | 177 (28.1 %) | 38 (21.2 %) | 3.387 | 0.184 | b | 681 (54 %) | 179 (50 %) | 1.17 (0.93–1.48) | 0.187 |
| TaqI | |||||||||
| TT | 224 (35.6 %) | 69 (39 %) | |||||||
| Tt | 325 (51.6 %) | 74 (41.8 %) | T | 773 (61.3 %) | 212 (59.9 %) | ||||
| tt | 81 (12.9 %) | 34 (19.2 %) | 7.032 | 0.030 | t | 487 (38.7 %) | 142 (40.1 %) | 0.94 (0.74–1.20) | 0.622 |
| ApaI | |||||||||
| AA | 232 (36.7 %) | 68 (38.6 %) | |||||||
| Aa | 312 (49.3 %) | 91 (51.7 %) | A | 776 (61.3 %) | 227 (64.5 %) | ||||
| aa | 89 (14.1 %) | 17 (9.7 %) | 2.343 | 0.310 | a | 490 (38.7 %) | 125 (35.5 %) | 1.15 (0.90–1.47) | 0.292 |
Genotypic and allelic association analysis of VDR single-nucleotide polymorphisms between NWNA and CUWA
| SNP | Genotypic association | Allelic association | |||||||
|---|---|---|---|---|---|---|---|---|---|
| NWNA ( | CUWA ( |
|
| NWNA ( | CUWA ( | OR (95 % CI) |
| ||
| BsmI | |||||||||
| BB | 127 (20.1 %) | 11 (17.5 %) | |||||||
| Bb | 327 (51.8 %) | 32 (50.8 %) | B | 581 (46 %) | 54 (42.8 %) | ||||
| bb | 177 (28.1 %) | 20 (31.7 %) | 0.492 | 0.782 | b | 681 (54 %) | 72 (57.2 %) | 0.88 (0.61–1.27) | 0.513 |
| TaqI | |||||||||
| TT | 224 (35.6 %) | 28 (45.9 %) | |||||||
| Tt | 325 (51.6 %) | 20 (32.8 %) | T | 773 (61.3 %) | 76 (62.3 %) | ||||
| tt | 81 (12.9 %) | 13 (21.3 %) | 8.492 | 0.014 | t | 487 (38.7 %) | 46 (37.7 %) | 1.04 (0.71–1.53) | 0.922 |
| ApaI | |||||||||
| AA | 232 (36.7 %) | 19 (31.1 %) | |||||||
| Aa | 312 (49.3 %) | 34 (55.7 %) | A | 776 (61.3 %) | 72 (59 %) | ||||
| aa | 89 (14.1 %) | 8 (13.1 %) | 0.966 | 0.617 | a | 490 (38.7 %) | 50 (41 %) | 0.91 (0.62–1.33) | 0.628 |
Detailed genotypic analysis between NWNA and CUW and between NWNA and CUWA
| SNP | NWNA ( | CUW ( | ORa | NWNA ( | CUWA ( | ORa |
|---|---|---|---|---|---|---|
| BsmI | ||||||
| BB/Bb | 454 (71.9 %) | 141 (78.8 %) | 454 (71.9 %) | 43 (68.3 %) | ||
| bb | 177 (28.1 %) | 38 (21.2 %) | 0.70 (0.47–1.04) | 177 (28.1 %) | 20 (31.7 %) | 1.19 (0.68–2.09) |
| TaqI | ||||||
| TT/Tt | 549 (87.1 %) | 143 (80.8 %) | 549 (87.1 %) | 48 (78.7 %) | ||
| tt | 81 (12.9 %) | 34 (19.2 %) | 1.59 (1.02–2.50) | 81 (12.9 %) | 13 (21.3 %) | 1.80 (0.93–3.48) |
| ApaI | ||||||
| AA/Aa | 544 (85.9 %) | 159 (90.3 %) | 544 (85.9 %) | 53 (86.9 %) | ||
| aa | 89 (14.1 %) | 17 (9.7 %) | 0.66 (0.38–1.14) | 89 (14.1 %) | 8 (13.1 %) | 0.86 (0.41–1.94) |
aAdjusted for vitamin deficiency status (<20 ng/ml)
Stratified genotypic analysis of TaqI among NWNA and CUW and NWNA and CUWA
| Whole population | Low vitamin D stratum (≤20 ng/ml) | High vitamin D stratum (>20 ng/ml) |
| |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SNP TaqI | ( | ( | ORa | ( | ( | ORa | ( | ( | ORa | |
| NWNA | CUW | NWNA | CUW | NWNA | CUW | |||||
| TT/Tt | 549 (87.1 %) | 143 (80.8 %) | 183 (82.4 %) | 46 (80.7 %) | 357 (89.5 %) | 96 (81.4 %) | ||||
| tt | 81 (12.9 %) | 34 (19.2 %) | 1.59 (1.02–2.50) | 39 (17.6 %) | 11 (19.3 %) | 1.13 (0.54–2.38) | 42 (10.5 %) | 22 (18.6 %) | 1.97 (1.12–3.46) | 0.245 |
| NWNA | CUWA | NWNA | CUWA | NWNA | CUWA | |||||
| TT/Tt | 549 (87.1 %) | 48 (78.7 %) | 183 (82.4 %) | 19 (79.2 %) | 357 (89.5 %) | 29 (78.4 %) | ||||
| tt | 81 (12.9 %) | 13 (21.3 %) | 1.80 (0.93–3.48) | 39 (17.6 %) | 5 (20.8 %) | 1.24 (0.44–3.54) | 42 (10.5 %) | 8 (21.6 %) | 2.37 (1.02–5.52) | 0.348 |
aAdjusted for vitamin deficiency status (≤20 ng/ml)